Try as we might, we can’t cover all the biotech news out there. During the week, we only pick the top stories to keep you informed but not waste your time. Here’s a roundup of news that didn’t make the cut this week.
- Sanofi has acquired Warp Drive Bio’s antibiotics program, which was born out of a strategic partnership among the French pharma, Third Rock Ventures and Greylock Partners.
- Takeda has injected €100M into a dengue vaccine manufacturing plant in Konstanz, Germany.
- Evonik’s €45M bid for a methionine fermentative production plant owned by METEX has been accepted.
- Ergomed has acquired PharmInvent to boost its PrimeVigilance unit, which monitors drugs that have been licensed for use.
- After a price cut, a leukemia pill from J&J wins market approval in the UK.
- Janssen submitted a MAA to the EMA for guselkumab to treat moderate to severe plaque psoriasis. It just submitted a BLA to the FDA two weeks ago.
- Ablynx reached its first milestone in a collaboration with Novo Nordisk on a multispecific Nanobody.
- Another patient has died on Carmat‘s watch. The company was careful to specify that the cause of death was not related to the experimental artificial heart implant that the company is developing.
- Czech scientists have created a 3D-printed lung model to simulate treatment of asthma and other chronic diseases.
- MDMA (yes, ecstasy) is set to hit Phase III clinical trials as a PTSD therapy. There is increasing enthusiasm for investigating medicinal benefits of illicit drugs.
That’s All, Folks!
Rodent or Kiwi?
Image Credits: Scenic Shutterbug, Dragos Raban, Roop_Dey, Uwe Bergwitz / shutterstock.com
Are you interested in respiratory disease R&D?
Download Inpart’s latest report, exploring the current research challenges, R&D trends, and breakthrough innovations in respiratory diseases.
